Vanda is a distressed, cash-burning specialty-pharma turnaround whose late-2026 launches and pipeline catalysts could unlock substantial upside—or expose shareholders to dilution.
Overview
Vanda is a specialty biopharmaceutical company whose revenue comes almost entirely from net product sales across psychiatry, multiple sclerosis, sleep medicine, motion sickness, and orphan immunology. The portfolio is at a critical inflection point: Hetlioz is being rapidly displaced by generics, while Fanapt is growing and Bysanti, Nereus, and Quimilza provide major launch and regulatory optionality. **Fanapt sales rose 23% to $36.0 million in Q2 2026 and prescriptions increased 31%, but total revenue still fell 4% to $50.5 million because Hetlioz declined 66% to $5.6 million.** The company reported a $62.5 million GAAP net loss and burned $93.8 million in the first half, leaving $170.0 million of cash and marketable securities. At a $5.43 share price, Vanda’s approximately $181.01 million enterprise value equals only 0.84x TTM sales of $215.72 million. The valuation discounts a potentially distressed outcome, but the near-term catalysts are substantial: Bysanti’s H2 2026 launch, Nereus Phase III GLP-1 data, and Quimilza’s December 12, 2026 FDA decision. The central debate is whether expense moderation and launch execution can precede liquidity stress.